![conference banner](/images/conference-banner.jpeg)
摘要
脂肪代谢障碍是一种常见的并发症,感染艾滋病毒的患者接受高活性抗逆转录病毒疗法。它的早期诊断,及时修改抗逆转录病毒治疗的关键。我们推测,在血浆中线粒体DNA可能是LD的艾滋病毒感染者的潜在标志物。在这项研究中,我们比较了艾滋病毒感染者和非HIV感染者血浆线粒体DNA水平,以探讨其潜在的诊断价值。 血浆总DNA从67个 HIV感染患者在基线和第12,24和30个月启动抗逆转录病毒治疗后提取。实时定量PCR法测定血浆中的线粒体DNA水平。脂肪代谢障碍是由医师评估存在脂肪萎缩或脂肪增生的一个或多个身体区域限定。在血浆中的线粒体DNA水平显著高于基线的艾滋病毒感染者比非HIV感染者(P <0)。一个月内67个病人中有30或33(49.2%)个至少有一个脂肪代谢障碍信号占2%。在24个月内,脂肪代谢障碍患者的平均血浆线粒体DNA水平显著高于那些没有脂肪代谢障碍,(P <0.001)。接收器工作曲线分析表明,利用等离子体线粒体DNA水平具有截止值> 5.09 log10拷贝/毫升)作为分子标记允许鉴定患者脂肪代谢障碍与64.2%的灵敏度和73.0%的特异性。我们的数据表明,线粒体DNA水平可能有助于指导治疗选择与指导HIV脂肪代谢障碍的风险。
关键词: 生物标志物,高效抗转录病毒治疗,人体免疫缺损病毒(HIV),脂肪代谢障碍,线粒体DNA,等离子体。
Current Molecular Medicine
Title:Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Volume: 15 Issue: 10
Author(s): Z. Dai, W. Cai, F. Hu, Y. Lan, L. Li, C. Chung, B. Caughey, K. Zhang and X. Tang
Affiliation:
关键词: 生物标志物,高效抗转录病毒治疗,人体免疫缺损病毒(HIV),脂肪代谢障碍,线粒体DNA,等离子体。
摘要: Lipodystrophy is a common complication in HIV-infected patients taking highly active antiretroviral therapy. Its early diagnosis is crucial for timely modification of antiretroviral therapy. We hypothesize that mitochondrial DNA in plasma may be a potential marker of LD in HIV-infected individuals. In this study, we compared plasma mitochondrial DNA levels in HIV-infected individuals and non-HIV-infected individuals to investigate its potential diagnostic value.
Total plasma DNA was extracted from 67 HIV-infected patients at baseline and 12, 24 and 30 months after initiating antiretroviral therapy. Real-time quantitative PCR was used to determine the mitochondrial DNA levels in plasma. Lipodystrophy was defined by the physician-assessed presence of lipoatrophy or lipohypertrophy in one or more body regions.
The mitochondrial DNA levels in plasma were significantly higher at baseline in HIV-infected individuals than in non-HIV-infected individuals (p<0.05). At month 30, 33 out of 67 patients (49.2%) showed at least one sign of lipodystrophy. The mean plasma mitochondrial DNA levels in lipodystrophy patients were significantly higher compared to those without lipodystrophy at month 24 (p<0.001). The receiver operating curve analysis demonstrated that using plasma mitochondrial DNA level (with cut-off value >5.09 log10 copies/ml) as a molecular marker allowed identification of patients with lipodystrophy with a sensitivity of 64.2% and a specificity of 73.0%.
Our data suggest that mitochondrial DNA levels may help to guide therapy selection with regards to HIV lipodystrophy risk.
Export Options
About this article
Cite this article as:
Z. Dai, W. Cai, F. Hu, Y. Lan, L. Li, C. Chung, B. Caughey, K. Zhang and X. Tang , Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART)., Current Molecular Medicine 2015; 15 (10) . https://dx.doi.org/10.2174/1566524016666151123114401
DOI https://dx.doi.org/10.2174/1566524016666151123114401 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Treatment Strategies Against Psoriasis: Principle, Perspectives and Practices
Current Drug Delivery Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Protease Inhibitor Monotherapy as Maintenance Regimen in Patients With HIV Infection
Current HIV Research Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry Management of Obesity
Current Respiratory Medicine Reviews Non Alcoholic Fatty Liver: Epidemiology and Natural History
Reviews on Recent Clinical Trials Targeting Trypanosoma cruzi Platelet-activating Factor Receptors: Scope for the Development of Novel Drugs to Treat Chagas Disease
Mini-Reviews in Medicinal Chemistry Experimental Methods and Transport Models for Drug Delivery Across the Blood-Brain Barrier
Current Pharmaceutical Biotechnology Gender And Susceptibility To Sepsis Following Trauma
Endocrine, Metabolic & Immune Disorders - Drug Targets Is the Carotid Plaque Rupture a Pivotal Event in Stroke Pathogenesis? Update on the Role of the Intraplaque Inflammatory Processes
Current Vascular Pharmacology Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Verbascum sinaiticum: A Rich Source of Antioxidant Phenylethanoid Glycosides
The Natural Products Journal Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Current Vascular Pharmacology A Viewpoint on Angiotensin-Converting Enzyme 2, Anti-Hypertensives and Coronavirus Disease 2019 (COVID-19)
Infectious Disorders - Drug Targets Vitamin D and Sepsis: From Associations to Causal Connections
Inflammation & Allergy - Drug Targets (Discontinued) Unorthodox Inhibitors of HIV Protease: Looking Beyond Active-site-directed Peptidomimetics
Current Pharmaceutical Design Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
Current Vascular Pharmacology